NCT02089347View on ClinicalTrials.gov

Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old

PHASE3CompletedINTERVENTIONAL

Enrollment

534

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

March 31, 2015

Conditions

TetanusDiphtheriaPertussis

Interventions

BIOLOGICAL

Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed

0.5 mL, intramuscularly.

BIOLOGICAL

Diphtheria and Tetanus toxoids adsorbed

0.1 mL, Subcutaneously

Trial Locations (19)

451 8511

Aichi

299 4503

Chiba

910 0833

Fukui

918 8205

Fukui

372 0817

Gunma

655 0017

Hyōgo

312 0057

Ibaraki

890 0034

Kagoshima

223 0051

Kanagawa

381 0025

Nagano

701 0205

Okayama

712 8064

Okayama

574 0046

Osaka

420 8623

Shizuoka

426 0067

Shizuoka

146 0023

Tokyo

146 0095

Tokyo

167 0052

Tokyo

183 0042

Tokyo

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02089347 - Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old | Biotech Hunter | Biotech Hunter